返回 Agenda
Session 9: Use of Artificial Intelligence in Clinical Trial Transparency
Session Chair(s)
Robert Paarlberg, MS
Principal
Paarlberg & Associates LLC, United States
Artificial Intelligence (AI) is having a major impact on life sciences. Its ability to process vast quantities of data and information faster than humans has numerous valuable applications in the sector, from creating new drugs and targets, to preparing documents for regulatory submissions to health authorities. This session will explore the use of leveraging AI in creating documents, using AI to modernize the Plain Language Summary process, and hearing about patient and public perceptions on the use of AI in crating clinical trial documents.
Learning Objective : - Understand how AI agents can automate mundane tasks in clinical trial documentation and disclosure
- Identify opportunities for implementing AI agents in clinical trial transparency processes
-
Explore the integration of AI technology into the PLS writing process
- Describe patient and public perceptions and preference on the use of AI to create plain language clinical trial documents
Speaker(s)
Leveraging AI Agents to Enhance Clinical Trial Transparency and Efficiency
Woo Song
Xogene, United States
Co-Founder
Modernizing the BMS PLS Process, Accelerating with AI Support
Lauren Haggerty
Bristol-Myers Squibb, United States
Clinical Trial Manager II
Patient and Public Perceptions on the Use of AI in Creating Clinical Trial Documents
Zack Fey
CISCRP, United States
Manager, Medical Writing